Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009384 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
A Phase 2 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02009384: Clinical Trial Phase 2 study, sponsored by University of Louisville.
NCT02009384 is a Phase 2 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02009384, a Phase 2 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will be enrolled and treated in the study.
Primary Outcome
no outcomes available, Study was Terminated due to low subject enrollment \[r/t requirement of prior treatment with denileukin diftitox\] Data was not analyzed
Interventions
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Why NCT02009384 stopped before completion
NCT02009384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT02009384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02009384 about?
NCT02009384 is a clinical study titled "Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox". This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will...
What is the current status of trial NCT02009384?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02009384?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02009384?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02009384's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia